. 2024 Nov 8;14(11):1423. doi: 10.3390/biom14111423

Table 1.

(A). Baseline characteristics of the study cohort for model development: obese BS patients (n = 24). (B). Baseline characteristics of the model validation cohort: obese BS patients (n = 15). (C). Baseline characteristics of the model validation cohort: non-morbidly obese MASLD patients (n = 10).

(A)
	Mean	SD	Median	IQR	Min	Max	Disease Stage (% of Patients)
							0	1	2	3	4
Age (years)	46	12	47	21	26	63
Gender Female (%)	71%
BMI Max (kg/m²)	46	8	44	6	36	77
BMI Surgery (kg/m²)	38	5	37	4	31	51
Glucose (mg/dL)	102	22	92	18	83	172
HbA1c (%)	5.8	0.8	5.5	0.6	4.7	7.9
Insulin (µU/mL)	14.7	5.1	13.9	9.8	8.5	24.5
HOMA-IR	3.7	1.5	3.7	2.0	1.9	7.3
Cholesterol (mg/dL)	171	51	169	59	70	280
HDL (mg/dL)	42	11	43	12	26	65
LDL (mg/dL)	101	48	104	44	10	199
Triglycerides (mg/dL)	140	62	134	61	67	304
AST (IU/L)	19	6	17	6	11	38
ALT (IU/L)	24	13	19	13	10	57
ALP (IU/L)	79	22	70	24	45	138
Bilirubin (mg/dL)	0.59	0.61	0.45	0.17	0.25	2.48
Albumin (g/dL)	4.3	0.3	4.3	0.4	3.6	4.8
PT (s)	11.5	0.8	11.5	1.1	10.0	12.8
Hemoglobin (g/dL)	14	2	14	2	12	17
Platelets (10³/µL)	259	57	248	61	174	377
Histopathology
% Steatosis—Digital HE-Stained Image	3.2	3.9	1.8	2.9	0.2	14.7
Steatosis	1.1	0.8	1.0	1.0	0	3	21%	50%	25%	4%
Balooning	0.5	0.7	0.0	1.0	0	2	61%	26%	13%
Lobular Inflammation	0.7	0.6	1.0	1.0	0	2	35%	61%	4%
Overall Activity	1.3	1.1	1.0	2.0	0	4	29%	33%	25%	8%	4%
Fibrosis	0.4	0.9	0.0	0.3	0	4	75%	21%	0%	0%	4%
MRI-PDFF
% Steatosis	10	7	8	8	2	30
(B)
	Mean	SD	Median	IQR	Min	Max	Disease Stage (% of Patients)
							0	1	2	3	4
Age (years)	51	10	53	14	31	63
Gender Female (%)	67%
BMI Max (kg/m²)	47	8	46	7	39	73
BMI Surgery (kg/m²)	41	7	38	5	33	63
Glucose (mg/dL)	96	8	98	14	83	108
HbA1c (%)	5.3	0.4	5.4	0.5	4.6	6.2
Insulin (µU/mL)	16.9	6.9	15.9	8.4	6.8	31.8
HOMA-IR	4.0	1.5	4.2	2.3	1.7	7.3
Cholesterol (mg/dL)	167	34	166	28	126	271
HDL (mg/dL)	43	7	42	12	31	53
LDL (mg/dL)	94	28	90	16	54	177
Triglycerides (mg/dL)	149	63	148	101	65	274
AST (IU/L)	20	4	21	6	13	27
ALT (IU/L)	24	9	23	13	10	40
ALP (IU/L)	70	13	69	14	50	101
Bilirubin (mg/dL)	0.76	0.22	0.76	0.29	0.50	1.20
Albumin (g/dL)	4.4	0.2	4.4	0.2	4.0	4.8
PT (s)	11.2	0.5	11.1	0.6	10.0	11.9
Hemoglobin (g/dL)	14	1	14	2	12	17
Platelets (10³/µL)	217	56	211	48	112	307
Histopathology
% Steatosis—Digital HE-Stained Image	4.7	3.0	3.7	3.0	1.1	12.3
Steatosis	1.3	0.5	1.0	1.0	1	2	0%	67%	33%	0%
Balooning	0.7	0.6	1.0	1.0	0	2	40%	53%	7%	0%
Lobular Inflammation	0.9	0.3	1.0	0.0	0	1	7%	93%	0%	0%
Overall Activity	1.5	0.8	2.0	1.0	0	3	13%	27%	53%	7%	0%
Fibrosis	0.4	0.5	0.0	1.0	0	1	60%	40%	0%	0%	0%
MRI-PDFF
% Steatosis	12	5	10	6	6	26
(C)
	Mean	SD	Median	IQR	Min	Max	Disease Stage (% of Patients)
							0	1	2	3	4
Age (years)	54	10	52	11	42	74
Gender Female (%)	40%
BMI (kg/m²)	31	4	30	4	25	38
Glucose (mg/dL)	119	48	97	37	85	241
HbA1c (%)	6.0	1.3	5.7	0.3	4.6	9.1
Insulin (µU/mL)	22.2	16.9	15.6	14.2	4.0	61.0
HOMA-IR	6.4	5.8	4.4	4.6	1.3	17.9
Cholesterol (mg/dL)	196	31	197	50	149	244
HDL (mg/dL)	49	24	40	11	26	109
LDL (mg/dL)	106	32	102	21	73	177
Triglycerides (mg/dL)	215	128	173	121	91	505
AST (IU/L)	57	45	36	51	19	156
ALT (IU/L)	66	41	59	42	19	134
ALP (IU/L)	72	30	64	46	44	124
Bilirubin (mg/dL)	0.67	0.29	0.61	0.21	0.25	1.30
Albumin (g/dL)	4.6	0.2	4.6	0.3	4.4	5.0
PT (s)	13.8	1.6	14.5	2.9	12.0	16.1
Hemoglobin (g/dL)	15	1	15	1	12	17
Platelets (10³/µL)	248	48	267	77	173	294
Histopathology
% Steatosis—Digital HE-Stained Image	7.5	6.2	7.4	9.2	1.1	18.9
Steatosis	1.7	1.2	2.0	1.8	0	3	20%	20%	30%	30%
Balooning	0.7	0.7	1.0	1.0	0	2	40%	50%	10%
Lobular Inflammation	0.8	0.4	1.0	0.0	0	1	20%	80%	0%
Overall Activity	1.5	1.0	2.0	1.0	0	3	20%	20%	50%	10%	0%
Fibrosis	1.1	1.2	1.0	1.8	0	3	40%	30%	10%	20%	0%
MRI-PDFF
% Steatosis	ND	ND	ND	ND	ND	ND